Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P L Collins

Showing results (121-130 of 160) with videos related to

Pageof 16
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1987
Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virusP L Collins, R A Olmsted, M K Spriggs, et al.
Journal of Virology|April 3, 1998
Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1T Tao, A P Durbin, S S Whitehead, et al.
The Journal of General Virology|August 1, 1989
Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinantsB R Murphy, P L Collins, L Lawrence, et al.
Journal of Virology|June 23, 2000
Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidatesT Tao, M H Skiadopoulos, F Davoodi, et al.
Vaccine|April 9, 1999
The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutationsK Juhasz, S S Whitehead, C A Boulanger, et al.
Biology of Reproduction|November 4, 2000
Gestational changes in uterine L-type calcium channel function and expression in guinea pigP L Collins, J J Moore, D W Lundgren, et al.
American Journal of Obstetrics and Gynecology|January 1, 1993
Ritodrine: a beta-adrenergic receptor antagonist in human amnionP L Collins, E Zink, R M Moore, et al.
Virology|October 1, 1987
Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirusK L van Wyke Coelingh, B R Murphy, P L Collins, et al.
Virology|September 1, 1997
Recovery of infectious human parainfluenza virus type 3 from cDNAA P Durbin, S L Hall, J W Siew, et al.
Virology|July 16, 1999
Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutationM H Skiadopoulos, S R Surman, M St Claire, et al.
Pageof 16

Showing results (121-130 of 160) with videos related to

Sort By:
Pageof 16
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1987
Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virusP L Collins, R A Olmsted, M K Spriggs, et al.
Journal of Virology|April 3, 1998
Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1T Tao, A P Durbin, S S Whitehead, et al.
The Journal of General Virology|August 1, 1989
Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinantsB R Murphy, P L Collins, L Lawrence, et al.
Journal of Virology|June 23, 2000
Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidatesT Tao, M H Skiadopoulos, F Davoodi, et al.
Vaccine|April 9, 1999
The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutationsK Juhasz, S S Whitehead, C A Boulanger, et al.
Biology of Reproduction|November 4, 2000
Gestational changes in uterine L-type calcium channel function and expression in guinea pigP L Collins, J J Moore, D W Lundgren, et al.
American Journal of Obstetrics and Gynecology|January 1, 1993
Ritodrine: a beta-adrenergic receptor antagonist in human amnionP L Collins, E Zink, R M Moore, et al.
Virology|October 1, 1987
Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirusK L van Wyke Coelingh, B R Murphy, P L Collins, et al.
Virology|September 1, 1997
Recovery of infectious human parainfluenza virus type 3 from cDNAA P Durbin, S L Hall, J W Siew, et al.
Virology|July 16, 1999
Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutationM H Skiadopoulos, S R Surman, M St Claire, et al.
Pageof 16